Open access · CC-BY
via OpenAlex
Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy
Jean Christopher Chamcheu, Tithi Roy, Mohammad B. Uddin, Sergette Banang‐Mbeumi, Roxane‐Cherille N. Chamcheu, Anthony L. Walker, Yu Liu, Shile Huang
Cells · 2019 · ▲ 212 citations
Epigenetic alterations
Deregulated nutrient-sensing
Altered intercellular communication
Rapamycin / mTOR inhibition
Human
Preclinical / animal
Review
Abstract
The mammalian or mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) and associated phosphatidyl-inositiol 3-kinase (PI3K)/protein kinase B (Akt) pathways regulate cell growth, differentiation, migration, and survival, as well as angiogenesis and metabolism. Dysregulation of these pathways is frequently associated with genetic/epigenetic alterations and predicts poor treatment outcomes in a variety of human cancers including cutaneous malignancies like melanoma and non-melanoma skin cancers. Recently, the enhanced understanding of the molecular and genetic basis of skin dysfunction in patients with skin cancers has provided a strong basis for the development of novel therapeutic strategies for these obdurate groups of skin cancers. This review summarizes recent advances in the roles of PI3K/Akt/mTOR and their targets in the development and progression of a broad spectrum of cutaneous cancers and discusses the current progress in preclinical and clinical studies for the development of PI3K/Akt/mTOR targeted therapies with nutraceuticals and synthetic small molecule inhibitors.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/cells8080803
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Chamcheu, J.C., Roy, T., Uddin, M.B., Banang‐Mbeumi, S., Chamcheu, R.N., Walker, A.L., Liu, Y., & Huang, S. (2019). Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. <em>Cells</em>. https://doi.org/10.3390/cells8080803
Vancouver
Chamcheu JC, Roy T, Uddin MB, Banang‐Mbeumi S, Chamcheu RN, Walker AL, et al. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Cells. 2019. doi:10.3390/cells8080803.
BibTeX
@article{jean2019Rolean,
title = {Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy},
author = {Jean Christopher Chamcheu and Tithi Roy and Mohammad B. Uddin and Sergette Banang‐Mbeumi and Roxane‐Cherille N. Chamcheu and Anthony L. Walker and Yu Liu and Shile Huang},
journal = {Cells},
year = {2019},
doi = {10.3390/cells8080803},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Molecular Sciences 2021
Open access · CC-BY
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Oncotarget 2010
Open access · OA
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
Journal of Clinical Medicine 2020
Open access · CC-BY
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Research and Reports in Biology 2015
Open access · CC-BY
Recent insights into the pathophysiology of mTOR pathway dysregulation
Cells 2023
Open access · CC-BY
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
Annals of Medicine 2014
Open access · OA